About Sun Pharma
Sun Pharmaceuticals was established by Mr.
Dilip Shanghvi
in 1983 in
Vapi
,
Gujarat
with five
products to treat
psychiatry
ailments. Cardiology products were introduced in 1987 followed by
gastroenterology
products in 1989. Today, it is the largest chronic prescription company in India
and a market leader in
psychiatry
, neurology, cardiology,
orthopedics
,
ophthalmology
,
gastroenterology and
nephrology
. Over 72% of Sun Pharma sales are from markets outside
India, primarily in States. US is the single largest market, accounting for about 50% turnover; in
all, formulations or finished dosage forms, account for 93% of the turnover. Manufacturing is
across 26 locations, including plants in US, Canada, Brazil, Mexico and Israel. In US, the
company markets a large basket of generics, with a strong pipeline awaiting approval from the
U.S. Food and Drug Administration (FDA). Sun Pharma was listed on the stock exchange in
1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake
in the company. Today Sun Pharma is the second largest and the most profitable pharmaceutical
company in India, as well as the largest pharmaceutical company by market capitalisation on the
Indian exchanges. The 2014 acquisition of
Ranbaxy
has made the company the largest
pharma
company
You've reached the end of your free preview.
Want to read both pages?
- Fall '19
- Generic drug, Ranbaxy Laboratories, Sun Pharmaceutical Industries Ltd, Sun Pharma sales
